If approved, the gene therapy Roctavian will likely launch at a list price of ~$2.5 million. But experts anticipate considerable discounts in most instances of sales, as many hemophilia A patients will have the product administered in a 340B-eligible treatment center, at a 340B discounted price.
When Launched, Gene Therapy Roctavian Will Be Administered Mainly In 340B-Eligible Treatment Centers, Where It Will Be Substantially Discounted In Price
